Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifamycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | ABCC4 | O15439 | 4/20 | 0.70 |
| ▸ | ABCC2 | Q92887 | 4/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | ABCC3 | O15438 | 3/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifamycin SCHEMBL22389512 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL31715824 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL2320 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL182452 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL151824 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL23370269 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL29649054 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL22553368 | 1.00 | ABCB11 (1.00) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL22389517 | 0.99 | ABCB11 (0.99) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 | |
| Rifamycin SCHEMBL29816867 | 0.99 | ABCB11 (0.99) | ABCB11TBXA2RCHRM1PTGS1SLCO2B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 716 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4057998-B1 | PROCESS FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION FOR ORAL INTAKE AND DRUG RELEASE IN THE COLON | ETHYPHARM SA (FR) | 2026-05-13 | — | — | EP | claimed |
| EP-4363415-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2025-12-10 | — | — | EP | claimed |
| EP-4469463-B1 | RIFAMYCIN DERIVATIVES FOR THE TREATMENT OF DISEASES | BioVersys AG (CH) | 2025-10-29 | — | — | EP | claimed |
| EP-3868378-B1 | SOLID DISPERSION OF RIFAMYCIN-NITROIMIDAZOLE COUPLING MOLECULES AND USE THEREOF | TENNOR THERAPEUTICS SUZHOU LTD (CN) | 2025-09-03 | — | — | EP | claimed |
| CN-119506336-A | Application of plant lectin encoding gene OsChtBL1 in rice stripe virus resistance | 宁波大学 | 2025-02-25 | — | — | CN | claimed |
| EP-3706724-B1 | ORAL RIFAMYCIN SV COMPOSITIONS | COSMO TECHNOLOGIES LTD (IE) | 2024-09-11 | — | — | EP | claimed |
| EP-3656785-B1 | ANTIMICROBIAL ADHESIVE PROTEIN, ANTIMICROBIAL NANOPARTICLE, ANTIMICROBIAL COMPOSITION COMPRISING SAME NANOPARTICLE, AND PREPARATION METHOD FOR SAME COMPOSITION | POSCO CO LTD (KR) | 2024-09-11 | — | — | EP | claimed |
| EP-4122470-B1 | METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS | INSMED INC (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4081304-B1 | ANTIBACTERIAL QUINOLINES | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2024-03-06 | — | — | EP | claimed |
| EP-3529359-B1 | TUMOR INFILTRATING LYMPHOCYTES FOR USE IN THERAPY | UNIV MINNESOTA (US) | 2023-12-13 | — | — | EP | claimed |
| EP-3122757-B1 | CHARGED LINKERS AND THEIR USES FOR CONJUGATION | HANGZHOU DAC BIOTECH CO LTD (CN) | 2023-09-06 | — | — | EP | claimed |
| EP-3252040-B1 | STABILIZER FOR PRESERVING BIOLOGICAL SAMPLES | BGI SHENZHEN (CN) | 2023-04-19 | — | — | EP | claimed |
| WO-2023002506-A1 | COMPOSITIONS OF SOPHOROLIPIDS FOR POTENTIAL USE IN THE TREATMENT OF TUBERCULOSIS AND MULTIDRUG RESISTANT TUBERCULOSIS | GODREJ INDUSTRIES LTD (CHEMICALS) (IN) | 2023-01-26 | — | — | WO | claimed |
| CN-112501211-B | Method for genetic transformation of eucommia ulmoides by injection | 贵州大学 | 2022-11-01 | — | — | CN | claimed |
| EP-4076561-A1 | CATHETER DEVICE FOR RELEASING PHARMACEUTICALLY ACTIVE COMPOUNDS OVER AN EXTENDED PERIOD | Cirlo GmbH (DE) | 2022-10-26 | — | — | EP | claimed |
| CN-109415412-B | Antibacterial peptide with synergistic antibacterial effect on gram-negative multidrug-resistant bacteria with antibiotics and application thereof | 建国大学校产学协力团 | 2022-10-04 | — | — | CN | claimed |
| EP-4057998-A1 | PROCESS FOR PRODUCING AN ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION WITH COLONIC DELIVERY | Ethypharm (FR) | 2022-09-21 | — | — | EP | claimed |
| EP-3288554-B1 | USE OF ANTIBIOTICS WITH SPECIFIC THERAPEUTIC ACTIVITIES COMBINED WITH THE SIMULTANEOUS USE OF LACTOBACILLI AND/OR BIFIDOBACTERIA WITH A NON-TRANSFERABLE ANTIBIOTIC RESISTANCE, HAVING THE SAME THERAPEUTIC INDICATION | PROBIOTICAL SPA (IT) | 2022-08-24 | — | — | EP | claimed |
| EP-3766501-B1 | METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS | INSMED INC (US) | 2022-07-06 | — | — | EP | claimed |
| EP-3500254-B1 | PHARMACEUTICAL COMPOSITION CONTAINING POLYMYXIN B/TRIMETHOPRIM BASED THERAPEUTICS | UNIV ROCHESTER (US) | 2022-03-23 | — | — | EP | claimed |